The Army created a new, safe vaccine for the Zika virus

Three Phase-1 human clinical trials evaluating an Army-developed Zika purified inactivated virus vaccine, known as a ZPIV, have shown it was safe and well-tolerated in healthy adults and induced a robust immune response. Initial findings from the trials were published early in December in the medical journal “The Lancet.”

Each of the three studies included in the paper was designed to address a unique question about background immunity, vaccine dose or vaccination schedule. A fourth trial with ZPIV is still underway in Puerto Rico, where the population has natural exposure to other viruses in the same family as Zika (flaviviruses), such as dengue.

A team of U.S. Army researchers at the Walter Reed Army Institute of Research are developing a Zika vaccine that has induced a strong immune response in early trials. (Photo Credit: U.S. Army photo by Jonathan Thompson, WRAIR)

A team of U.S. Army researchers at the Walter Reed Army Institute of Research are developing a Zika vaccine that has induced a strong immune response in early trials. (U.S. Army photo by Jonathan Thompson, WRAIR)

“It is imperative to develop a vaccine that prevents severe birth defects and other neurologic complications in babies caused by Zika virus infection during pregnancy,” said Dr. Kayvon Modjarrad, WRAIR’s Director for Emerging Infectious Diseases, the Zika program co-lead and the article’s lead author. “These results give us hope that a safe and effective vaccine will be achievable.”

Across the three trials, a total of 67 healthy adult volunteers (55 vaccine, 12 placebo) received two vaccine injections, four weeks apart. Researchers measured the immune response by monitoring levels of Zika virus-neutralizing antibodies in the blood. More than 90% of volunteers who received the vaccine developed an immune response against Zika.

Read More: Here’s what US troops should do if they’re worried about Zika

“Not only is the development of a Zika vaccine a global public health priority, but it is also necessary to protect Service Members and their families,” said Col. Nelson Michael, director of WRAIR’s Military HIV Research Program and Zika program co-lead.

The ZPIV vaccine candidate was developed as part of the U.S. Department of Defense response to the 2015 outbreak of Zika virus in the Americas. WRAIR researchers conceived the ZPIV vaccine in February 2016 and were able to advance the candidate to a Phase 1 human trial by November of the same year.

“WRAIR has previously steered to licensure a similar vaccine for Japanese encephalitis, a flavivirus in the same family as Zika, which helped speed our vaccine development effort,” said Dr. Leyi Lin, who led one of the trials at WRAIR.

A team of U.S. Army researchers at the Walter Reed Army Institute of Research are developing a Zika vaccine that has induced a strong immune response in early trials. (Photo Credit: U.S. Army photo by Jonathan Thompson, WRAIR)

A team of U.S. Army researchers at the Walter Reed Army Institute of Research are developing a Zika vaccine that has induced a strong immune response in early trials. (U.S. Army photo by Jonathan Thompson, WRAIR)

In the volunteers who received the vaccine, neutralizing antibody levels peaked two weeks after they completed the 2-dose vaccine series, and exceeded the threshold established in an earlier study needed to protect monkeys against a Zika virus challenge. Researchers also found that antibodies from vaccinated volunteers protected mice from a Zika virus challenge, providing insight into how this vaccine might prevent Zika infection.

Next steps include evaluating how long vaccine-induced immunity lasts, and the impact of dose, schedule and background immunity. Michael added that, “Army researchers are part of integrated, strategic US Government effort to develop a vaccine to protect against Zika.”

The ZPIV program is led by Col. Michael and Dr. Modjarrad. The principal investigators at each of the study sites were Dr. Leyi Lin at WRAIR, Dr. Sarah L. George at SLU and Dr. Kathryn E. Stephenson at BIDMC. The sponsor of the investigational new drug application for two of the studies (WRAIR and SLU) is the National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases, part of the National Institutes of Health. The BIDMC study is investigator-sponsored by Dr. Kathryn Stephenson.

A team of U.S. Army researchers at the Walter Reed Army Institute of Research are developing a Zika vaccine that has induced a strong immune response in early trials. (Photo Credit: U.S. Army photo by Jonathan Thompson, WRAIR)

A team of U.S. Army researchers at the Walter Reed Army Institute of Research are developing a Zika vaccine that has induced a strong immune response in early trials. (U.S. Army photo by Jonathan Thompson, WRAIR)

 

TOP ARTICLES
This Army veteran's book focuses on the stories of the 'Frontline Generation'

Eastman's goal was to capture the lessons she learned that represents the best of what it means to be American — the 1% of the population in the military.

Nigeria will spend a billion dollars to fight Boko Haram

Boko Haram, once one of the most feared groups in Africa, is still a problem. Nigeria, however, has decided they aren't putting up with them anymore.

ISIS may have obtained anti-tank missiles from the CIA

Somehow, ISIS has gotten a hold of weapons purchased by the CIA and Saudi Arabia and dispersed, without permission from either, to allied fighters.

How the Army plans to counter massive drone attacks

The United States military is experiencing more and more drone attacks in combat zones, and they have a plan to start shooting them down faster.

Marines want to swarm enemy defenses with hundreds of small boats

It looks like the Marine Corps is ready to get their own boats instead of borrowing them from the Navy all the time. Is this the end of water taxis?

This bearded Marine brings joy to the Corps

He's making a gear list. He's checking it twice. Gonna find out who's boot or grunt. Gunny Clause is coming on base. So stand at ease, kiddos.

This new device helps amputees manage phantom limb pain

Amira Idris designed a device helps amputees experiencing the phenomenon known as phantom limb pain (PLP) — and now she's giving the device to vets.

5 stories you may have missed for the week of December 16th

With everything going on in the world, it's difficult to keep track of every story that pops up. Check the stories you may have missed this week.

This is why the U.S.military uses 5.56mm ammo instead of 7.62mm

A common debate among gun enthusiasts revolves around why the U.S. chose to implement the 5.56mm N.A.T.O. round into service instead of the 7.62mm.

Combat Flip Flops are all about freedom — and not just for your feet

Buy a comfy pair of flip flops — put Afghanistan to work. Buy your lady a sarong — put an Afghan girl through school. This is global democracy, step two.